The use of transient elastography and fibrotest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis

JAMA Dermatology

Volumn 150, Issue 8, 2014, Pages 856-862

  Lynch, Maeve ^a   Higgins, Eleanor ^a   McCormick, P Aiden ^a   Kirby, Brian ^a   Nolan, Niamh ^a   Rogers, Sarah ^a   Lally, Aoife ^a   Vellinga, Akke ^b   Omar, Haniza ^a   Collins, Paul ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; METHOTREXATE; PROCOLLAGEN;

ADULT; AGE; AGED; ARTICLE; BLOOD LEVEL; BODY MASS; ECHOGRAPHY; ELASTOGRAPHY; FATTY LIVER; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; LIVER FUNCTION TEST KIT; LIVER SINUSOID; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; OBESITY; OUTPATIENT DEPARTMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; SCORING SYSTEM;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BIOPSY; BODY MASS INDEX; DRUG MONITORING; DRUG-INDUCED LIVER INJURY; ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; FEMALE; FIBROSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; MALE; METHOTREXATE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROCOLLAGEN; PSORIASIS; YOUNG ADULT;

EID: 84906766343     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.9336     Document Type: Article

References (48)

1. Aithal GP, Haugk B, Das S, Card T, Burt AD, Record CO. Monitoringmethotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aliment Pharmacol Ther. 2004;19(4):391-399. (Pubitemid 38297107)
2. Zachariae H. Liver biopsies and methotrexate: a time for reconsideration? J AmAcad Dermatol. 2000;42(3):531-534. (Pubitemid 30470371)
3. Zachariae H. Havemethotrexate-induced liver fibrosis and cirrhosis become rare? a matter for reappraisal of routine liver biopsies. Dermatology. 2005;211(4):307-308. (Pubitemid 41642101)
4. Boffa MJ, Chalmers RJ, Haboubi NY, Shomaf M, Mitchell DM. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol. 1995;133(5):774-778.
5. Chalmers RJ, Kirby B, Smith A, et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol. 2005;152(3):444-450. (Pubitemid 40547117)
6. Maurice PDL, Maddox AJ, Green CA, Tatnall F, Schofield JK, Stott DJ. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen. Br J Dermatol. 2005;152(3):451-458. (Pubitemid 40547118)
7. Roenigk HH Jr, Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference. J AmAcad Dermatol. 1998;38(3):478-485. (Pubitemid 28125534)
8. Kalb RE, Strober B,Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009;60(5):824-837.
9. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4: guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J AmAcad Dermatol. 2009;61(3):451-485.
10. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England andWales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut. 1995;36(3):437-441.
11. Lichtinghagen R, Bahr MJ. Noninvasive diagnosis of fibrosis in chronic liver disease. Expert Rev Mol Diagn. 2004;4(5):715-726. (Pubitemid 39220844)
12. Zachariae H, Aslam HM, Bjerring P, Søgaard H, Zachariae E, Heickendorff L. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. J AmAcad Dermatol. 1991;25(1, pt 1):50-53.
13. Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011;11:91. doi:10.1186/1471-230X-11-91.
14. Talwalkar JA, Kurtz DM, Schoenleber SJ,West CP, Montori VM. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2007;5(10):1214-1220. (Pubitemid 47488974)
15. The non-invasive tests, alternative to liver biopsy. BioPredictive website. http://www.biopredictive.com/intl/physician. Accessed May 1, 2014.
16. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol. 2007;102(11):2589-2600. (Pubitemid 47631778)
17. Bedossa P, Poynard T; METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996;24(2):289-293. (Pubitemid 26260021)
18. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343-350. (Pubitemid 40439195)
19. Berends MA, Snoek J, de Jong EM, et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int. 2007;27(5):639-645. (Pubitemid 47097314)
20. Bray AP, Barnova I, Przemioslo R, Kennedy CT. Liver fibrosis screening for patients with psoriasis taking methotrexate: a cross-sectional study comparing transient elastography and liver biopsy. Br J Dermatol. 2012;166(5):1125-1127.
21. Leonard O, Woolf R, Jiyad Z, Martyn-Simmons CL, Barker JNWN, Smith CH. Risk factors for liver fibrosis in patients with severe psoriasis established on methotrexate: a cross-sectional cohort study. Br J Dermatol. 2012;167(suppl 1):68.
22. Laharie D, Seneschal J, Schaeverbeke T, et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study. J Hepatol. 2010;53(6):1035-1040.
23. Barbero-Villares A, Mendoza J, Trapero-Marugan M, et al. Evaluation of liver fibrosis by transient elastography inmethotrexate treated patients. Med Clin (Barc). 2011;137(14):637-639.
24. Castéra L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51(3):828-835.
25. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41(1):48-54. (Pubitemid 40066382)
26. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol. 2004;3(1):8. doi:10.1186/1476-5926-3-8.
27. Montaudié H, Sbidian E, Paul C, et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol. 2011;25(suppl 2):12-18.
28. Suárez-Zarracina T, Valle-Garay E, Collazos J, et al. Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients. J Viral Hepat. 2012;19(10):685-693.
29. Blanco F, Barreiro P, Ryan P, et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat. 2011;18(1):11-16.
30. Poynard T, Zoulim F, Ratziu V, et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol. 2005;100(9):1970-1980.
31. Fraquelli M, Rigamonti C, Casazza G, et al. Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C. J Hepatol. 2011;54(4):621-628.
32. Kirk GD, Mehta SH, Astemborski J, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med. 2013;158(9):658-666.
33. Masuzaki R, Tateishi R, Yoshida H, et al. Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography. J Clin Gastroenterol. 2008;42(7):839-843.
34. de Lédinghen V, Barreiro P, Foucher J, et al. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. J Viral Hepat. 2008;15(6):427-433. (Pubitemid 351677550)
35. de Lédinghen V, Vergniol J, Gonzalez C, et al. Screening for liver fibrosis by using FibroScan and FibroTest in patients with diabetes. Dig Liver Dis. 2012;44(5):413-418.
36. Petit JM, Guiu B, Masson D, et al. PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes. Liver Int. 2011;31(9):1332-1336.
37. Poynard T, Lebray P, Ingiliz P, et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol. 2010;10:40. doi:10.1186/1471-230X-10-40.
38. Zelber-Sagi S, Ratziu V, Zvibel I, et al. The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury: a study in the general population. Eur J Gastroenterol Hepatol. 2012;24(3):262-269.
39. Sirli R, Sporea I, Tudora A, Deleanu A, Popescu A. Transient elastographic evaluation of subjects without known hepatic pathology: does age change the liver stiffness? J Gastrointestin Liver Dis. 2009;18(1):57-60.
40. Salles N, Dussarat P, Foucher J, Villars S, de Lédinghen V. Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients. Gastroenterol Clin Biol. 2009;33(2):126-132.
41. Poynard T, Ingiliz P, Elkrief L, et al. Concordance in a world without a gold standard: a new non-invasivemethodology for improving accuracy of fibrosis markers. PLoS One. 2008;3(12):e3857. doi:10.1371/journal.pone.0003857.
42. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51(4):758-764.
43. Langman G, Hall PM, Todd G. Role of non-alcoholic steatohepatitis in methotrexateinduced liver injury. J Gastroenterol Hepatol. 2001; 16(12):1395-1401. (Pubitemid 34107409)
44. Anastasiou J, Alisa A, Virtue S, Portmann B, Murray-Lyon I, Williams R. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. Eur J Gastroenterol Hepatol. 2010;22(4):474-480.
45. Boffa MJ, Smith A, Chalmers RJ, et al. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol. 1996;135(4):538-544. (Pubitemid 26341933)
46. Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol. 2008;32(6)(suppl 1):22-39.
47. Poynard T, Morra R, Ingiliz P, et al. Biomarkers of liver fibrosis. Adv Clin Chem. 2008;46:131-160.
48. Teare JP, Sherman D, Greenfield SM, et al. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet. 1993;342(8876):895-898. (Pubitemid 23291593)